This might be the biggest breakthrough in pancreatic cancer in decades
A new clinical trial has shown promising results for a drug targeting a genetic mutation found in most pancreatic cancer tumors, potentially doubling survival rates. The drug, daraxonrasib, has been found to improve median survival from 6.7 months to 13.2 months when combined with chemotherapy.
A recent phase 3 clinical trial has demonstrated that the drug daraxonrasib, designed to target the KRAS genetic mutation, may nearly double survival outcomes in patients with pancreatic cancer when combined with chemotherapy. The KRAS mutation is present in nearly 90% of pancreatic cancer tumors and helps regulate cell growth. When mutated, it causes cells to divide uncontrollably. Daraxonrasib binds to the altered protein, blocking signals that drive uncontrolled growth. In the trial, patients receiving the drug lived a median of 13.2 months, compared to 6.7 months for those who did not. This breakthrough is significant, as pancreatic cancer is one of the deadliest cancers. The drug is a once-daily oral medication and could usher in a new generation of treatments for pancreatic cancer.
This content was automatically generated and/or translated by AI. It may contain inaccuracies. Please refer to the original sources for verification.